Long-term follow-up of kidney transplant recipients in the spare-the-nephron-trial

Transplantation

Volumn 101, Issue 1, 2017, Pages 157-165

  Weir, Matthew R ^a   Pearson, Thomas C ^b   Patel, Anita ^c   Peddi, Ram V ^d   Kalil, Roberto ^e   Scandling, John ^f   Chan, Lawrence ^g   Baliga, Prabhakar ^h   Melton, Larry ⁱ   Mulgaonkar, Shamkant ^j   Waid, Thomas ^k   Schaefer, Heidi ^l   Youssef, Nasser ^m   Anandagoda, Lali ^a   McCollum, David ⁿ   Lawson, Sibylle ⁿ   Gordon, Robert ⁿ  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j SAINT BARNABAS MEDICAL CENTER   (United States)

^k UNIVERSITY OF KENTUCKY   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^m OUR LADY OF LOURDES MEDICAL CENTER   (United States)

ⁿ CTI Clinical Trial and Consulting Services   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS;

ACUTE CORONARY SYNDROME; ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BK VIRUS INFECTION; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC GRAFT REJECTION; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; GLIOBLASTOMA; GRAFT FAILURE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENCE; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; THYROID CANCER; UTERINE CERVIX CANCER; VASCULAR DISEASE; VEIN OCCLUSION; ADVERSE EFFECTS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SUBSTITUTION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEPHRON; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; CALCINEURIN INHIBITORS; CYCLOSPORINE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEPHRONS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84960173069     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001098     Document Type: Article

References (10)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl JMed. 2003;349:2326-2333.
2. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol. 2003;14:1940-1948.
3. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011;79:897-907.
4. Weir MR, Diekmann F, Flechner SM, et al. mTOR inhibition: the learning curve in kidney transplantation. Transpl Int. 2010;23:447-460.
5. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011;11:1633-1644.
6. Isakova T, Xie H, Messinger S, et al. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am J Transplant. 2013;13:100-110.
7. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant. 2011;11:1665-1675.
8. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233-242.
9. Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119-128.
10. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and metaanalysis of individual patient data. BMJ. 2014;349:g6679.